The Promise and Price of Gene Therapies
New cell and gene therapies (CGTs) are offering great promise and tremendous challenges for the US healthcare system but with shocking initial costs. These groundbreaking treatments represent a significant leap forward in medical science, potentially offering permanent cures for previously untreatable conditions. However, their arrival comes with unprecedented price tags that threaten to strain both individual patients and the broader healthcare infrastructure.
Revolutionary Treatments with Revolutionary Price Tags
For example, gene therapy with exagamglogene autotemcel (Casgevy) might permanently stave off vaso-occlusive crises in some patients with sickle cell anemia. But this product arrived on the market with a $2.2 million price tag. This single-dose therapy represents decades of research and development, yet its cost places it far beyond the reach of most patients and insurance systems. Similar gene therapies for other conditions carry comparable price points, ranging from hundreds of thousands to several million dollars per treatment.
Understanding the Cost Challenge
The pricing crisis extends beyond individual treatments to affect the entire healthcare ecosystem. Insurance companies struggle to manage these one-time, high-cost interventions within traditional payment models. Patients face impossible choices between life-changing treatments and financial devastation. Healthcare systems must balance budget constraints against the ethical imperative to provide cutting-edge care.
Impact on Healthcare Accessibility
These astronomical costs create significant barriers to access, particularly for patients without comprehensive insurance coverage or those whose insurers deny coverage for experimental treatments. The disparity in access threatens to widen existing healthcare inequalities, with only the most privileged patients able to benefit from these medical breakthroughs.
A Single-Payer Solution for Cell and Gene Therapies
For that reason, health policy researcher Stacie Dusetzina, PhD, of Vanderbilt University School of Medicine, Nashville, Tennessee, has suggested a single-payer program as a new approach for handling the costs of gene therapies and cell-based therapies such as CD19-directed chimeric antigen receptor T-cell treatments.
Dual Implementation Pathways
In an article in JAMA Internal Medicine, Dusetzina and coauthor, Audun Brendbekken, MD, of the University of Bergen, Bergen, Norway, said such a program could be operated through private entities or through a carve out of the Medicare insurance program. This flexible approach would allow policymakers to choose the most practical implementation strategy based on existing infrastructure and political feasibility.
The private entity model would leverage existing insurance mechanisms while creating a dedicated pool for gene therapy funding. Alternatively, the Medicare carve-out approach would expand the federal insurance program to cover these specific high-cost treatments regardless of patient age or traditional eligibility criteria.
The Medicare ESRD Precedent
Congress has a model for this approach rooted in healthcare history. In 1972, lawmakers wanted to make kidney dialysis, then an innovative and costly treatment, available to people who were too young for Medicare. Congress passed a law, allowing those with end-stage renal disease (ESRD) to enroll in Medicare.
Lessons from Historical Healthcare Expansion
This precedent demonstrates that Congress can create carve-outs for specific treatments when the medical and economic justifications align. The ESRD program has successfully provided life-saving dialysis and kidney transplants to hundreds of thousands of Americans over five decades, proving that targeted expansions of coverage can work effectively within the American healthcare system.
Implementation Through Value-Based Pricing
“For eligible treatments, the single payer would ideally adopt value-based price negotiation strategies so as not to supplant other health care priorities,” Dusetzina and Brendbekken wrote. “Methods for negotiation could mirror those implemented under the Inflation Reduction Act’s Medicare Drug Price Negotiation program.”
Balancing Innovation and Affordability
This negotiation framework would ensure that pharmaceutical companies receive fair compensation for their research investments while preventing unsustainable pricing that locks patients out of treatment. Value-based pricing considers long-term healthcare savings, improved patient outcomes, and comparative effectiveness against existing therapies.
Future Implications for Healthcare Access
The proposed single-payer model for gene therapies could transform how America approaches high-cost medical innovations. By pooling risk and negotiating collectively, the system could ensure broader access while maintaining incentives for continued research and development. This approach may become increasingly necessary as more gene therapies receive FDA approval and enter the market in coming years.
Discover the latest payers’ news updates with a single click. Follow DistilINFO HealthPlan and stay ahead with updates. Join our community today!
